Effect of Age and Age‐Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies
Neurogastroenterology & Motility · 2026
DOI: 10.1111/nmo.70429 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neurogastroenterology & Motility, 2026. Verfasst von Lin Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Constipation, Guanylyl Cyclase C Agonists, Irritable Bowel Syndrome, Menopause. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ironwood Pharmaceuticals, Incorporated, AbbVie.
Abstract (Originalsprache)
Background
This post hoc study explored the effect of age and age‐defined menopausal status on linaclotide efficacy and safety in adults with irritable bowel syndrome with constipation (IBS‐C) or chronic idiopathic constipation (CIC).
Methods
Data were pooled from eight randomized, placebo‐controlled studies of linaclotide 72 μg (CIC), 145 μg (CIC), or 290 μg (IBS‐C). Patients were stratified by age (< 65 years; ≥ 65 years) and female patients by age‐defined menopausal status (premenopausal: ≤ 45 years; postmenopausal: > 45 years) as a surrogate for clinically confirmed menopausal status. Efficacy endpoints included change from baseline and time to response in complete spontaneous bowel movement (CSBM) frequency and abdominal symptoms.
Results
Linaclotide increased weekly CSBM frequency from baseline versus placebo across age (IBS‐C, < 65 years, placebo: 0.8; 290 μg: 2.3; ≥ 65 years, placebo: 0.9; 290 μg: 2.6; CIC, < 65 years, placebo: 0.7; 72 μg: 1.7; 145 μg: 2.0; ≥ 65 years, placebo: 0.9; 72 μg: 1.5; 145 μg: 2.3) and menopausal subgroups. Abdominal symptoms reduced from baseline versus placebo across all subgroups. Median time (weeks) to an increase from baseline in weekly CSBM rate of ≥ 1 was shorter with linaclotide versus placebo across age (IBS‐C, < 65 years, placebo: 4.0; 290 μg: 2.0; ≥ 65 years, placebo: 3.0; 290 μg: 2.0; CIC, < 65 years, placebo: 4.0; 72 μg: 3.0; 145 μg: 2.0; ≥ 65 years, placebo: 5.0; 72 μg: 3.0; 145 μg: 1.5) and age‐defined menopausal subgroups.
Conclusion
In this exploratory post hoc analysis, linaclotide was associated with improvements in bowel and abdominal symptoms across age and age‐defined menopausal subgroups, with a safety profile consistent with previous studies, suggesting that age and menopausal status did not meaningfully influence treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Gastroenterology, Hepatology and Healthcare Acquired Infection, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
- Ironwood Pharmaceuticals, Inc., Boston, Massachusetts, USA.
- AbbVie Inc., Chicago, Illinois, USA.
- Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Lin Chang, Kyle Staller, Lesley A Houghton, Paul Feuerstadt, Darren M Brenner
Förderung
- Ironwood Pharmaceuticals, Incorporated
- AbbVie
Zitieren
APA
Chang, L., Staller, K., Houghton, L. A., Yerneni, N., Higgins, S., Chen, W., Wu, J., Ford, A. C., Feuerstadt, P., & Brenner, D. M. (2026). Effect of Age and Age‐Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70429
Vancouver
Chang L, Staller K, Houghton LA, Yerneni N, Higgins S, Chen W, et al. Effect of Age and Age‐Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies. Neurogastroenterology & Motility. 2026. doi:10.1111/nmo.70429
BibTeX
@article{Chang2026,
author = {Chang, Lin and Staller, Kyle and Houghton, Lesley A and Yerneni, Niha and Higgins, Sally and Chen, Wendy and Wu, James and Ford, Alexander C and Feuerstadt, Paul and Brenner, Darren M},
title = {Effect of Age and Age‐Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies},
journal = {Neurogastroenterology & Motility},
year = {2026},
doi = {10.1111/nmo.70429}
}
EUVIMED